Atavistik Bio Strengthens Executive Team By Appointing Susan Pandya, M.D., As Chief Medical Officer

Atavistik Bio, a biotechnology company focused on developing next-generation precision allosteric therapeutics, has announced the appointment of Susan Pandya, M.D., as its new Chief Medical Officer (CMO). Dr. Pandya brings two decades of drug development expertise, including a strong record of achieving regulatory approvals, leading high-performing teams, and delivering innovative precision medicines to address unmet patient needs.

In her new role as CMO, Dr. Pandya will oversee all aspects of Atavistik Bio’s clinical development strategy and operations. This includes guiding the ongoing Phase 1 clinical trial of ATV-1601, the company’s lead program, which is an allosteric selective inhibitor designed to target AKT1 E17K-driven solid tumors. She will also be instrumental in advancing Atavistik Bio’s preclinical pipeline into well-planned and efficient clinical studies.

Bryan Stuart, Chief Executive Officer at Atavistik Bio, stated, “We are very excited to welcome Susan to the Atavistik Bio team as we transition to a clinical stage organization. Susan’s expertise in guiding oncology programs through early development, global registration studies, and marketing approval will be instrumental as we progress the ongoing clinical study of our lead precision allosteric candidate, ATV-1601, while continuing to rapidly advance our other pipeline programs toward the clinic.”

“Atavistik Bio’s commitment to discovering and developing both best-in-class and first-in-class allosteric therapeutics for significantly underserved patient populations represents an important advancement in the field of precision oncology medicine,” mentioned Dr. Pandya. “I am thrilled to join this exceptional team at such a pivotal time for the company, and I look forward to helping advance this exciting portfolio of novel precision allosteric therapeutics for patients in dire need of new therapeutic options.”

Dr. Pandya most recently served as Vice President of Clinical Development and Global Head of Late-Stage Oncology at Servier Pharmaceuticals, where she led all late-stage oncology and hematology programs. She also played an important role in corporate business development and portfolio strategy. Prior to her time at Servier, she led clinical development of the isocitrate dehydrogenase (IDH) inhibitor portfolio at Agios Pharmaceuticals, which was later acquired by Servier in 2021. During her career, she has contributed to multiple global drug approvals across various oncology indications. Earlier, she worked in early-phase development at Acceleron Pharma.

Dr. Pandya earned her medical degree from Tufts University School of Medicine and completed her residency in internal medicine followed by a fellowship in hematology/oncology. She also maintained a clinical practice at Beth Israel Deaconess Medical Center. In addition to her new role at Atavistik Bio, Dr. Pandya serves on the Board of Directors for MOMA Therapeutics.